Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Alvotech - Ordinary Shares
(NQ:
ALVO
)
11.55
+0.06 (+0.52%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 11, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
78,621
Open
11.59
Bid (Size)
4.630 (2)
Ask (Size)
13.96 (3)
Prev. Close
11.49
Today's Range
11.40 - 11.61
52wk Range
9.150 - 18.00
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Alvotech Reports Financial Results for the First Nine Months of 2024
November 13, 2024
From
Alvotech
Via
GlobeNewswire
Earnings Scheduled For November 13, 2024
November 13, 2024
Via
Benzinga
Performance
YTD
+1.67%
+1.67%
1 Month
-5.41%
-5.41%
3 Month
+7.34%
+7.34%
6 Month
-18.83%
-18.83%
1 Year
+24.19%
+24.19%
More News
Read More
Alvotech's Earnings Outlook
November 12, 2024
Via
Benzinga
Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore’s HealthCONx Conference on December 5, 2024
November 07, 2024
From
Alvotech
Via
GlobeNewswire
European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab)
November 04, 2024
From
Alvotech
Via
GlobeNewswire
ALVO Stock Earnings: Alvotech Misses Revenue for Q2 2024
August 15, 2024
Via
InvestorPlace
Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET
October 30, 2024
From
Alvotech
Via
GlobeNewswire
Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024
October 25, 2024
From
Alvotech
Via
GlobeNewswire
European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
October 10, 2024
From
Alvotech
Via
GlobeNewswire
Alvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio®
September 25, 2024
From
Alvotech
Via
GlobeNewswire
UnitedHealth Follows Competitors, Replaces Humira with Lower-Cost Biosimilars
September 11, 2024
Via
Benzinga
Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
August 26, 2024
From
Alvotech
Via
GlobeNewswire
Vipshop, Hesai Group And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
August 20, 2024
Via
Benzinga
Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024
August 15, 2024
From
Alvotech
Via
GlobeNewswire
European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
August 15, 2024
From
Alvotech
Via
GlobeNewswire
Alvotech to Report Financial Results for the First Half of 2024 on August 15, 2024, and Host Conference Call on August 16, 2024, at 8:00 am ET
August 01, 2024
From
Alvotech
Via
GlobeNewswire
STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe
July 22, 2024
From
Alvotech
Via
GlobeNewswire
Alvotech Announces Closing of Private Debt Financing
July 11, 2024
From
Alvotech
Via
GlobeNewswire
Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem
July 10, 2024
Via
MarketBeat
Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
July 02, 2024
From
Alvotech
Via
GlobeNewswire
Alvotech Issues New Shares to Holders of Convertible Bonds
July 01, 2024
From
Alvotech
Via
GlobeNewswire
Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024
July 01, 2024
From
Alvotech
Via
GlobeNewswire
Alvotech Receives Conversion Notices for Majority of Convertible Bonds
June 26, 2024
From
Alvotech
Via
GlobeNewswire
Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LD/HD in Europe
June 18, 2024
From
Alvotech
Via
GlobeNewswire
Alvotech and STADA add to strategic alliance through denosumab partnership
June 11, 2024
From
Alvotech
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.